Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research focused on Myeloid leukemia and CD33, with related work in Sorafenib, Multivariate analysis, Hypomethylating agent. Notable publications include 'Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group', 'A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia', and 'A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML'.
A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Sorafenib treatment following hematopoietic stem cell transplant in pediatric <i>FLT3</i>/ITD acute myeloid leukemia
High <i> <scp>EVI</scp> 1 </i> expression is associated with <i> <scp>MLL</scp> </i> rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report